Background: Optimal diabetes care and risk factor management are important to delay micro- and macrovascular complications in individuals with type 1 diabetes (T1D) . Ongoing improvement of management strategies requires the evaluation of target achievement and identification of determinants in individuals who do (or do not) achieve these targets.

Methods: Cross-sectional data were collected from individuals with T1D visiting Diabeter and the University Medical Center Groningen, the Netherlands, in 2018. Targets were defined as HbA1c <7%, LDL-c <2.6mmol/l (no CVD present) or <1.8mmol/l (CVD present) , or blood pressure (BP) <140/90mmHg. Determinants between individuals who did (or did not) achieve targets were compared by presence of CVD.

Results: Data from 1,737 individuals were available. Mean age was 27 [IQR 22-43] years and 50% female. Mean HbA1c was 63 mmol/mol (7.9%) , LDL-c was 2.67mmol/l, and BP 131/76mmHg. In individuals with CVD, 24%, 33%, and 46% achieved HbA1c, LDL-c, and BP targets respectively. In individuals without CVD these percentages were, 29%, 54%, and 77%, respectively. Individuals with CVD who did or did not achieve HbA1c targets did not differ significantly. Individuals who achieved LDL-c targets had a longer diabetes duration (42 vs. 37 years, p=0.03) , lower eGFR (eGFR 56 vs. 70 ml/min/kg2) and were prescribed more lipid lowering medication (94% vs. 77%, p=0.05) . Individuals who achieved BP targets were younger (58 vs. 62 years, p=0.05) . In comparison, individuals without CVD who achieved HbA1c targets differed in age (28 vs. 25 years, p=<.001) , sex (45% vs. 53% female, p=0.02) , and insulin pump use (60% vs 52%, p=0.01) amongst others. Those who achieved LDL-c targets had lower BMI (24.1 vs. 26.1kg/m2, p=<.001) . BP targets were achieved by younger individuals with less microvascular complications (14% vs. 33%, p=<.001) .

Conclusions: Opportunities for improvement diabetes management exist for the achievement of glycaemic, lipid and BP targets but differ between individuals with and without CVD.


R.D.M.Varkevisser: None. E.Birnie: None. C.E.Vollenbrock: None. D.Mul: None. P.Van dijk: None. M.M.Van der klauw: Advisory Panel; Pfizer Inc. H.J.Veeze: Employee; Medtronic. H.Aanstoot: Consultant; Lilly Diabetes, Medtronic. B.H.Wolffenbuttel: Advisory Panel; Novo Nordisk A/S, Other Relationship; Novo Nordisk.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at